Table 2.

Baseline clinical and haemodynamic characteristics between high and low serum S100A12 combined patients in both (UNC & Yale) cohorts

Variable	High S100A12 (≥21.2 ng/mL) (n = 66)	Low S100A12 (<21.2 ng/mL) (n = 25)	P-value
Age (years)	58 ± 15	56 ± 13	0.67
Female, n (%)	45 (68%)	15 (60%)	0.46
TRV	3.4 ± 0.9	3.6 ± 1.1	0.66
Mean PAP (mm Hg)	41.4 ± 12.9	42.4 ± 11.8	0.75
PVR (Wood units)	6.5 ± 4.6	5.8 ± 5.5	0.54
TD cardiac output (L/min)	4.8 ± 1.9	5.9 ± 1.9	0.02
S100A12 (ng/mL)	38.9 ± 12.6	13.1 ± 5.4	<0.0001
Survival (years)	2.1 ± 1.1	2.9 ± 0.7	<0.001
WHO PH groups:			NS
PH—Group I (n %)	35 (53%)	14 (53.8%)
PH—Group II (n %)	1 (1.5%)	0 (0%)
PH—Group III (n %)	23 (34.8%)	5 (19.2%)
PH—Group IV (n %)	4 (6.2%)	4 (15.4%)
PH—Group V (n %)	3 (4.5%)	3 (11.6%)

Results are reported as mean ± SD, unless otherwise stated.

P-values were calculated using the Fisher’s exact test except for age, TRV, mean PAP, TD cardiac output, where unpaired Student’s t-test was used.

NS, not significant; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; TD, thermo-dilution; TRV, tricuspid regurgitation jet velocity; UNC, University of North Carolina; WHO, World Health Organization.